Trending now:  
Semaglutide’s impact on obesity-related heart failure with preserved ejection fraction
NOAH-AFNET 6: Oral anticoagulation & atrial high rate episodes
ESC 2023 Highlights
ESC Congress 2023 Highlights
What to expect at ESC Congress 2023

Content for healthcare professionals only


News |

The 70th annual ESC 2022 Congress took place in Barcelona, Spain and online from 26 to 29 August. Here are our top 11 highlights from the congress. The prospective, randomized TIME trial followed 21,104 patients for over 5 years to evaluate any difference in outcomes associated with nighttime versus daytime dosing of antihypertensive medications. Heart attack, stroke and vascular death occurred at similar rates in all participants, regardless of if they took their antihypertensive medication in the morning or the evening1. ALL-HEART was the first and only large trial to date to investigate the effect of xanthine oxidase inhibitor allopurinol on cardiovascular disease (CVD) in patients with ischemic heart disease (IHD). ALL-HEART randomized 5721 patients with IHD to receive either allopurinol or placebo. After an average follow-up period of 4.8 years, there was no difference between the groups in the primary outcome of non-fatal myocardial infarction (MI), non-fatal stroke or cardiovascular (CV) death2.
30 Aug 2022